Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Korro Bio (KRRO) over the last 7 years, with Q3 2025 value amounting to $63.3 million.

  • Korro Bio's Non-Current Assets fell 3022.92% to $63.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $316.8 million, marking a year-over-year increase of 1396.08%. This contributed to the annual value of $94.7 million for FY2024, which is 9353.84% up from last year.
  • Per Korro Bio's latest filing, its Non-Current Assets stood at $63.3 million for Q3 2025, which was down 3022.92% from $77.8 million recorded in Q2 2025.
  • Korro Bio's Non-Current Assets' 5-year high stood at $94.7 million during Q4 2024, with a 5-year trough of $3.8 million in Q3 2023.
  • For the 5-year period, Korro Bio's Non-Current Assets averaged around $51.9 million, with its median value being $48.9 million (2023).
  • Per our database at Business Quant, Korro Bio's Non-Current Assets crashed by 8901.01% in 2023 and then soared by 225801.51% in 2024.
  • Quarter analysis of 5 years shows Korro Bio's Non-Current Assets stood at $50.6 million in 2021, then crashed by 67.08% to $16.7 million in 2022, then skyrocketed by 193.75% to $48.9 million in 2023, then skyrocketed by 93.54% to $94.7 million in 2024, then crashed by 33.14% to $63.3 million in 2025.
  • Its Non-Current Assets was $63.3 million in Q3 2025, compared to $77.8 million in Q2 2025 and $81.0 million in Q1 2025.